http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109718242-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| filingDate | 2019-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109718242-B |
| titleOfInvention | Interference RNA for inhibiting Rac1 expression and application thereof in increasing breast cancer chemotherapy sensitivity |
| abstract | The invention relates to the field of biological medicine, and particularly discloses an interference RNA for inhibiting Rac1 expression and application thereof in increasing breast cancer chemotherapy sensitivity, and further discloses a breast cancer chemotherapy drug, which comprises the interference RNA for inhibiting Rac1 expression, a chemotherapy drug and a carrier for conveying tumor microenvironment response of the interference RNA and the chemotherapy drug. The invention adopts acid-sensitive nano material as a carrier, can efficiently convey siRNA and chemotherapeutic drugs into tumor cells, has longer circulation time in blood and high enrichment in tumor; meanwhile, the siRNA and chemotherapy prodrug are loaded, so that the target gene can be silenced efficiently, the drug-resistant gene expression can be effectively inhibited, the killing effect on tumor cells can be enhanced, the tumor chemotherapy effect can be obviously improved, the toxic and side effects on normal tissue cells are small, and the siRNA and chemotherapy prodrug have no obvious damage to important organs such as heart, liver and the like. |
| priorityDate | 2019-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.